Literature DB >> 17487294

Noncardiogenic pulmonary edema associated with clopidogrel: a serious but unexpected side effect of clopidogrel.

Izzet Celal Erdinler1, Ekrem Ucer, Abdurrahman Eksik, Ahmet Akyol, Selcuk Yazici.   

Abstract

Clopidogrel has a favourable side effect profile, in which the most serious complications are related to bleeding diathesis. Drug reactions represent frequently encountered clinical problems that can also be life-threatening. In the present case, serious noncardiogenic pulmonary edema was observed as an idiosyncratic reaction after clopidogrel use. Using the Naranjo adverse drug reactions probability scale, a possible likelihood of this putative interaction between clopidogrel and pulmonary edema was calculated. Such an adverse effect of clopidogrel has never been reported before. The present report shows the importance of recognizing rare adverse reactions of newer drugs, such as clopidogrel, in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487294      PMCID: PMC2650669          DOI: 10.1016/s0828-282x(07)70788-2

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  9 in total

1.  Hemolytic uremic syndrome in a patient treated with clopidogrel.

Authors:  P H Oomen; J E Tulleken; J G Zijlstra
Journal:  Ann Intern Med       Date:  2000-06-20       Impact factor: 25.391

2.  Severe hypersensitivity associated with clopidogrel.

Authors:  F Sarrot-Reynauld; L Bouillet; J L Bourrain
Journal:  Ann Intern Med       Date:  2001-08-21       Impact factor: 25.391

3.  Fatal aplastic anaemia associated with clopidogrel.

Authors:  J M Trivier; J Caron; M Mahieu; N Cambier; C Rose
Journal:  Lancet       Date:  2001-02-10       Impact factor: 79.321

4.  Serum sickness-like reaction associated with clopidogrel.

Authors:  Elizabeth J Phillips; Sandra R Knowles; Neil H Shear
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Thrombotic thrombocytopenic purpura associated with clopidogrel.

Authors:  C L Bennett; J M Connors; J M Carwile; J L Moake; W R Bell; S R Tarantolo; L J McCarthy; R Sarode; A J Hatfield; M D Feldman; C J Davidson; H M Tsai
Journal:  N Engl J Med       Date:  2000-06-15       Impact factor: 91.245

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.

Authors:  L A Harker; J P Boissel; A J Pilgrim; M Gent
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

Review 9.  Adverse drug reactions: types and treatment options.

Authors:  Marc A Riedl; Adrian M Casillas
Journal:  Am Fam Physician       Date:  2003-11-01       Impact factor: 3.292

  9 in total
  1 in total

1.  Clopidogrel-Associated Interstitial Lung Disease: A Case Report and Literature Review.

Authors:  Sheeraz Abro; Viktoriya Bikeyeva; Warda A Naqvi; Chinyere L Anigbo; Farhan Tariq; Ramish Hussain Rafay; Muhammad Faiq Umar; Romil Singh
Journal:  Cureus       Date:  2022-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.